Product Images Clopidogrel Bisulfate

This is a product description for Clopidogrel Bisulfate tablets. The product has a product number of 6327-0 and contains 75mg of Clopidogrel Bisulfate. It is recommended to store the tablets at 87°F or under. The product comes with 30 tablets.*

The text provides a figure showing the incidence of fatal or non-fatal vascular events in the CAPRIE study, comparing the use of aspirin versus clopidogrel. It includes a cumulative event rate (%) graph with months of follow-up on the x-axis and the percentage of events on the y-axis.*

This is a figure showing the effect of coadministered proton pump inhibitors (PPIs) on the exposure to the active metabolite of the drug Clopidogrel. The figure includes a graph with the mean and 90% confidence intervals for the effect of Dexlansoprazole, Lansoprazole, Pantoprazole, and Omeprazole on the active metabolite area under the curve (AUC) relative to administering Clopidogrel alone.*

The text describes Figure 2 of the CURE study, which shows the cumulative event rate of cardiovascular death, myocardial infarction, and stroke in patients receiving placebo or clopidogrel, both of which were taken with aspirin. The figure displays the event rate over 12 months of follow-up, and other standard therapies were used when appropriate.*

The text describes the COMMIT study and provides a graph showing the cumulative event rates for death before discharge among patients receiving either placebo or clopidogrel. The graph suggests that clopidogrel was associated with a lower risk of death, with a 7% proportional risk reduction compared to placebo (p=0.03). All patients received aspirin.*

The figure shows the cumulative event rates for a combined endpoint (reinfarction, stroke, or death) in patients within 28 days after randomization. The study, known as COMMIT, involved patients who had suffered a heart attack and all received aspirin. The placebo group had 10.1% of 2,310 patients experiencing the combined endpoint while the clopidogrel group had 9.2% of 2,121 patients experiencing it. The proportional risk reduction for clopidogrel versus placebo was 9% (p=0.002). Days since randomization are shown on the X-axis.*